Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Depletion of Gln in vitro can lead to an impaired proliferation and dysfunction of T-lymphocytes 16,17,18
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
All handling must comply with applicable laboratory procedures, institutional protocols, and qualified research standards
Maintenance After Weight Loss Once youve met your weight loss goals, well work with you to create a long-term maintenance plan
Moderate medication interactions have been identified, and safety information is well characterized
AOD-9604: Does not cause receptor burnout Does not require washout periods Does not lose effectiveness due to continuous use Consistency, not cycling, aligns with how it was designed to work
US$ 28.43
US$ 25.85
US$ 20.98
